
Molecular Mechanism of Ferroptosis: An Overview

Ying Liu*

Department of Life Sciences, Fudan University, China



I c

Ferroptosis is a recently characterized form of regulated cell death

Minimal distribution of regulated cell death

Minimal distribution of regulated cell death

Unlike apoptosis, which involves caspase activation and

Research has revealed that ferroptosis is intricately linked to the property of the property o

Ferroptosis is a recently characterized form of regulated cell death that is distinct from traditional apoptosis, necrosis, and autophagy. First identi ed in 2012, ferroptosis is de ned by its reliance on iron and the accumulation of lipid peroxides, which leads to cellular dysfunction and death. is form of cell death has garnered signi cant attention due to its implications in various diseases, including cancer, neurodegenerative disorders, and ischemia-reperfusion injury. Unlike apoptosis, which involves caspase activation and chromatin fragmentation, or necrosis, which is typically a passive and uncontrolled process, ferroptosis is a highly regulated event triggered by speci c biochemical changes. Central to its mechanism is the interplay between iron metabolism, lipid metabolism, and antioxidant defenses. Dysregulation of these processes can render cells susceptible to ferroptosis, making it a key

player in cellular responses to stress [3].

Research has revealed that ferroptosis is intricately linked to multiple signaling pathways, including those involving p53, Nrf2, and mTORC1, which regulate cellular iron levels, lipid composition, and oxidative stress responses. For instance, p53 has been shown to in uence ferroptosis by upregulation the expression of proteins that promote lipid peroxidation while downregulating those that confer protection against oxidative damage. Similarly, Nrf2, a critical regulator of the cellular antioxidant response, plays a protective role by activating genes involved in glutathione synthesis and other antioxidant mechanisms [4].

e signi cance of ferroptosis extends to a variety of pathological contexts. In cancer, for example, many tumor cells develop resistance to ferroptosis, enabling them to survive in oxidative environments. Conversely, inducing ferroptosis in speci c cancer types may present a novel therapeutic strategy. In neurodegenerative diseases, the excessive activation of ferroptosis has been implicated in neuronal death, highlighting the need for therapeutic interventions that can modulate this form of cell death. Additionally, ferroptosis plays a role in ischemia-reperfusion injury, where the restoration of blood ow can trigger oxidative stress and lipid peroxidation, exacerbating tissue damage [5].

is overview aims to elucidate the molecular mechanisms underlying ferroptosis, examining the key players and pathways involved, as well as its relevance in various disease contexts. By understanding these mechanisms, we can better appreciate the therapeutic potential of ferroptosis modulation in clinical settings. As research in this area continues to evolve, it is anticipated that novel interventions targeting ferroptosis will emerge, o ering new hope for

Received: 01-Nov-2024, Manuscript No: cmb-24-149056; Editor assigned: 04-Nov-2024, PreQC No: cmb-24-149056(PQ); Reviewed: 18-Nov-2024, QC No: cmb-24-149056; Revised: 25-Nov-2024, Manuscript No: cmb-24-149056(R); Published: 30-Nov-2024, DOI: 10.4172/1165-158X.1000361

Citation: Ying L (2024) Molecular Mechanism of Ferroptosis: An Overview. Cell Mol Biol. 70: 361.

Copyright: © 2024 Ying L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

^{*}Corresponding author: Ying Liu, Department of Life Sciences, Fudan University, China, E-mail: Liu.ying@gmail.com

the treatment of diseases where this form of cell death plays a critical role [6].

D_{c}

e exploration of ferroptosis has illuminated its multifaceted role in cellular homeostasis and disease pathology. As a unique form of regulated cell death, ferroptosis presents a paradox: while it can contribute to detrimental outcomes in neurodegenerative diseases and tissue injury, it also o ers therapeutic opportunities in cancer treatment. is duality underscores the necessity of a nuanced understanding of ferroptosis, particularly regarding its molecular mechanisms and regulatory pathways. One of the key insights gained from recent studies is the signi cance of iron metabolism in ferroptosis. Elevated intracellular iron levels can catalyze the production of reactive oxygen species (ROS) through the Fenton reaction, leading to lipid peroxidation and subsequent cell death. is has led to the hypothesis that targeting iron homeostasis could be an e ective therapeutic strategy. Iron chelators, such as deferoxamine, have shown promise in mitigating ferroptosis-related damage in neurodegenerative models, suggesting that modulation of iron levels could protect vulnerable cells from oxidative stress [7].

Lipid peroxidation, another hallmark of ferroptosis, highlights the role of speci c fatty acids in determining cellular susceptibility to this form of death. e vulnerability of polyunsaturated fatty acids (PUFAs) to oxidation indicates that dietary or pharmacological interventions aimed at altering membrane lipid composition could in uence ferroptotic sensitivity. Moreover, the role of enzymes like lipoxygenases and acyl-CoA synthetase long-chain family member 4 (ACSL4) emphasizes the importance of lipid metabolic pathways in regulating ferroptosis. Future research could explore the potential of targeting these enzymes to either promote or inhibit ferroptosis, depending on the desired therapeutic outcome [8].

e intersection of ferroptosis with key signaling pathways further complicates its regulation. For instance, the involvement of the tumor suppressor p53 not only highlights the relationship between cellular stress responses and ferroptosis but also raises the possibility of exploiting this pathway in cancer therapy. Strategies that enhance p53-mediated ferroptosis in tumors could potentially overcome resistance mechanisms and improve treatment e cacy. Similarly, the role of Nrf2 in regulating antioxidant defenses suggests that enhancing its activity might provide a protective e ect against ferroptosis in neurodegenerative contexts, o ering a dual approach to both protect healthy cells and target tumor cells selectively [9].

As the research landscape continues to expand, the potential therapeutic applications of ferroptosis modulation become increasingly apparent. e development of ferroptosis inducers, such as Erastin and RSL3, has opened new avenues in cancer therapy, where inducing cell death in resistant tumor cells may enhance treatment responses.

Conversely, agents that inhibit ferroptosis could be bene cial in protecting against neurodegeneration and tissue damage in ischemia-reperfusion injury [10].

\mathbf{C}

In conclusion, the molecular mechanisms of ferroptosis reveal a complex interplay between iron metabolism, lipid peroxidation, and cellular signaling pathways. Understanding these interactions not only enhances our comprehension of ferroptosis itself but also provides critical insights into its therapeutic potential across a range of diseases. As we continue to unravel the intricacies of ferroptosis, it is imperative that future research focuses on translating these ndings into clinical applications, ultimately leveraging this unique form of cell death for improved patient outcomes.

Ac

None

C c I

None

References

- Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, et al. (2000) The relationship between geneticdamage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis 21: 1281-1289.
- Bagnoli F, Fady B, Fineschi S, Oddou- Muratorio S, Piotti A, et al. (2011) Neutral patterns of genetic variation and applications to conservation in conifer species. Genetics, genomics and breeding of conifers CRC Press. Boca Raton 28: 141-95.
- Yang SH, Galanis A, Witty J, Sharrocks AD (2006) An extended consensus
 EMBO J 25: 5083-93.
- Whitbread AK, Masoumi A, Tetlow N, Schmuck E, Coggan M, et al. (2005) Characterization of the omega class of glutathione transferases. Methods in Enzymology. 401: 78-99.
- Chronopoulou E, Ataya FS, Pouliou F, Perperopoulou F, Georgakis N, et al. (2017) Structure evolution and functional roles of plant glutathione transferases. Glutathione in plant growth, development, and stress tolerance. Springer London. 9: 195-213.
- Smith DB, Johnson KS (1988) expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67: 31-40.
- Vikis HG, Guan KL (2004) Glutathione-S-transferase-fusion based assays for studying protein-protein interactions. Methods Mol Biol 261: 175-186.
- Yip YL, Smith G, Ward RL (2001) Comparison of phage pIII, pVIII and GST as carrier proteins for peptide immunisation in Balb/c mice. Immunol Lett 79: 197-202.
- Smyth DR, Mrozkiewicz MK, McGrath WJ, Listwan P, Kobe B (2003) Crystal Protein Sci 12: 1313-1322.
- Singh CR, Asano K (2007) Localization and characterization of protein-protein interaction sites. Methods Enzymol 429: 39-161.